Sandoz Group has agreed to pay a total of US$478.5 million to resolve long-running US investigations into generic drug pricing, including US$400 million over seven years to US states and territories, and has separately received marketing authorization in Brazil for Owozy, a semaglutide product for diabetes patients. The US settlements crystallize a defined cash outflow profile and reduce the risk of further large, unexpected legal charges on the same matters. The Brazilian approval gives Sandoz Group commercial rights in an estimated US$1.8 billion local GLP-1 market, though management has guided to no material contribution in 2026. Both developments were announced in 2026 and affect the company's legal risk profile and access to a major emerging diabetes market.
Sandoz Group AGSettles US pricing cases, reducing legal risk, and gains Brazil approval for semaglutide, opening a large market.
